| P50 | author | Natalia Naumova | Q59539185 |
| P2093 | author name string | Alexey Boyko | |
| | Valentin Vlassov | |
| | Marsel R Kabilov | |
| | Tatiana Alikina | |
| | Madina Kozhieva | |
| P2860 | cites work | Sulfate-reducing bacteria in human feces and their association with inflammatory bowel diseases | Q61607084 |
| | The role of gut microbiota in shaping the relapse-remitting and chronic-progressive forms of multiple sclerosis in mouse models | Q64066255 |
| | Dietary Modulation of Intestinal Microbiota: Future Opportunities in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis | Q64108334 |
| | Mechanism of cholesterol reduction to coprostanol by Eubacterium coprostanoligenes ATCC 51222 | Q71492870 |
| | New age for progressive multiple sclerosis | Q90024856 |
| | Multiple sclerosis and faecal microbiome transplantation: are you going to eat that? | Q90333381 |
| | Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability | Q91318393 |
| | Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome | Q92253914 |
| | Short-chain fatty acids and gut microbiota in multiple sclerosis | Q93066507 |
| | A critical review of the relationship between dietary components, the gut microbe Akkermansia muciniphila, and human health | Q93143197 |
| | The role of microbiota in the pathogenesis of lupus: Dose it impact lupus nephritis? | Q93340177 |
| | Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS) | Q22241644 |
| | Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria | Q24605493 |
| | Oral Multiple Sclerosis Drugs Inhibit the In vitro Growth of Epsilon Toxin Producing Gut Bacterium, Clostridium perfringens | Q28818329 |
| | Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy | Q29547619 |
| | UPARSE: highly accurate OTU sequences from microbial amplicon reads | Q29616627 |
| | A study of dietary modification: Perceptions and attitudes of patients with multiple sclerosis. | Q30276281 |
| | Anaerofustis stercorihominis gen. nov., sp. nov., from human feces | Q31040738 |
| | Acidaminococcus intestini sp. nov., isolated from human clinical samples | Q31131910 |
| | Progressive multiple sclerosis: from pathogenic mechanisms to treatment. | Q31139925 |
| | Diagnosis of multiple sclerosis: progress and challenges | Q31144846 |
| | An improved dual-indexing approach for multiplexed 16S rRNA gene sequencing on the Illumina MiSeq platform | Q34039945 |
| | Molecular microbial diversity of an anaerobic digestor as determined by small-subunit rDNA sequence analysis | Q34431545 |
| | Metabolism of cholesterol and bile acids by the gut microbiota. | Q34533691 |
| | Analysis of the factors affecting the formation of the microbiome associated with chronic osteomyelitis of the jaw. | Q35013364 |
| | Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls | Q37040077 |
| | Microbiology of regressive autism | Q37971827 |
| | Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis | Q40400256 |
| | Phascolarctobacterium faecium abundant colonization in human gastrointestinal tract | Q41624596 |
| | Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice | Q42263596 |
| | A human stool-derived Bilophila wadsworthia strain caused systemic inflammation in specific-pathogen-free mice | Q44930677 |
| | Revised McDonald criteria for multiple sclerosis diagnostics in central Russia: sensitivity and specificity | Q45182882 |
| | The tension between early diagnosis and misdiagnosis of multiple sclerosis | Q47800390 |
| | Nature, nurture, and microbes: The development of multiple sclerosis | Q48001628 |
| | The "Gut Feeling": Breaking Down the Role of Gut Microbiome in Multiple Sclerosis | Q48047320 |
| | The microbiome and autoimmunity: a paradigm from the gut-liver axis. | Q52715835 |
| | No effects without causes: the Iron Dysregulation and Dormant Microbes hypothesis for chronic, inflammatory diseases. | Q53698735 |
| | Gut Microbiota Confers Resistance of Albino Oxford Rats to the Induction of Experimental Autoimmune Encephalomyelitis. | Q55166910 |
| | Intestinal Microbiota Influences Non-intestinal Related Autoimmune Diseases. | Q55195884 |
| | Bilophila wadsworthia aggravates high fat diet induced metabolic dysfunctions in mice | Q57114614 |
| | From Nose to Gut - The Role of the Microbiome in Neurological Disease | Q57295632 |
| | The Gut Microbiome in Multiple Sclerosis: A Potential Therapeutic Avenue | Q58704148 |
| P433 | issue | 1 | |
| P921 | main subject | bacterial diversity | Q129941212 |
| | primary progressive multiple sclerosis | Q18553470 |
| P304 | page(s) | 309 | |
| P577 | publication date | 2019-12-30 | |
| P1433 | published in | BMC Microbiology | Q15759430 |
| P1476 | title | Primary progressive multiple sclerosis in a Russian cohort: relationship with gut bacterial diversity | |
| P478 | volume | 19 | |